je.st
news
Tag: inhibitor
Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
2015-09-18 21:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the companys investigational beta-lactamase inhibitor for the treatment, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal infections, met its primary endpoint, and that Merck is now initiating pivotal Phase 3 studies. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Ian McConnell, (973) 901-5722orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
presented
phase
Fritz Industries, Inc. Brings Innovative Long-Term Scale and Paraffin Inhibitor Solution to Customers Globally
2015-09-17 12:31:11| Industrial Newsroom - All News for Today
New product line, previously custom manufactured for Baker Hughes, increases well production and reduces downtime MESQUITE, Texas Fritz Industries, a leading manufacturer of oilfield products, announced today that it has reached an agreement with Baker Hughes Incorporated. Under the terms of the agreement, Fritz...
Tags: solution
customers
scale
industries
Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
2015-09-16 16:16:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: on
type
similar
controlled
World's First Fully Integrated Anti-UAV Defence System (AUDS) Now Features Quad Band RF Inhibitor And Optical Disruptor
2015-09-15 07:20:18| rfglobalnet Home Page
The world's first fully integrated detect-track-disrupt Anti-UAV Defence System (AUDS) - launched by a trio of British companies in May this year – now features a quad band radio frequency (RF) inhibitor/jammer, an optical disruptor and rapid deployment features in the final production version of the market leading counter-drone system. These enhancements follow extensive customer trials of the pre-production system across Europe and North America over the spring and summer.
Tags: system
features
fully
band
World's First Fully Integrated Anti-UAV Defence System (AUDS) Now Features Quad Band RF Inhibitor and Optical Disruptor
2015-09-14 12:31:15| Industrial Newsroom - All News for Today
LONDON, - All British AUDS team - Blighter Surveillance Systems, Chess Dynamics and Enterprise Control Systems - adds new capability to production version of counter UAV/drone system following extensive government sponsored spring/summer trials - New features include a fourth inhibitor band, an optical disruptor...
Tags: system
features
fully
band